Abstract

BackgroundFactors affecting the risk of bleeding by bronchoscopic biopsy in patients with lung cancer remain unclear. The levels of plasma apolipoprotein E (ApoE) that may be associated with endobronchial biopsy (EBB)-induced bleeding have never been examined.MethodsThis was a retrospective study using data collected from 615 consecutive patients who had undergone EBB and been diagnosed with primary lung cancer from January 2014 through February 2018. Patients were either classified as the bleeding group (n = 214) or the non-bleeding group (n = 391) based on the bronchoscopy report. Multiple regression analysis was done to estimate the independent relationship between ApoE levels and EBB-induced bleeding, with an adjustment for potential confounders.ResultsThe mean plasma ApoE concentration was higher in the non-bleeding group compared to that in the bleeding group (P < 0.05). However, a non-linear relationship with threshold effects was observed between plasma ApoE levels and EBB-induced bleeding in a piecewise linear regression analysis. The risk of EBB-induced bleeding decreased with ApoE concentrations from 3.5 mg/dL up to 5.9 mg/dL (adjusted odds ratio, 0.64; 95% confidence interval, 0.43–0.94); however, the incidence of EBB-induced bleeding increased with ApoE levels above the turning point (ApoE = 5.9 mg/dL).ConclusionsThere was a non-linear association between plasma ApoE levels and the risk of EBB-induced bleeding. Higher plasma ApoE concentrations (> 5.9 mg/dL) are the independent risk factor for hemorrhage during EBB in patients with lung cancer.

Highlights

  • Factors affecting the risk of bleeding by bronchoscopic biopsy in patients with lung cancer remain unclear

  • Of 615 consecutive patients, 224 (36.4%) hemorrhaged during endobronchial biopsy (EBB), and they were subjected to hemostasis maneuvers

  • We found that middle levels of apolipoprotein E (ApoE) (3.5–5.9 mg/dL) associated well with a decreased risk of EBB-induced bleeding when compared to lower levels (< 3.5 mg/L); higher levels of ApoE (≧ 6.0 mg/L) did not associate with a decreased incidence of EBB-induced bleeding when compared to low level of ApoE (< 3.5 mg/L) (OR, 0.85; 95% Confidence interval (CI), 0.41–1.76; P > 0.05)

Read more

Summary

Introduction

Factors affecting the risk of bleeding by bronchoscopic biopsy in patients with lung cancer remain unclear. The levels of plasma apolipoprotein E (ApoE) that may be associated with endobronchial biopsy (EBB)-induced bleeding have never been examined. Patients with lung cancer are the main subjects who need bronchoscopy. Bronchoscopic biopsy is indispensable in histopathological diagnosis of endobronchial exophytic lesions [1]. Endobronchial biopsy (EBB) has been used for the diagnosis of lung disease for over. Hemorrhage is a very common complication for bronchoscopists during EBB. Malignant lesions are more likely subjected to bleed upon biopsy than benign mucosal lesions [5]. The rate of EBB-induced hemorrhage is over 30.0% in patients with lung cancer [6], and massive biopsy-related hemorrhage could be life-threatening [7, 8]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call